<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132414</url>
  </required_header>
  <id_info>
    <org_study_id>31-175 ex 18/19</org_study_id>
    <nct_id>NCT04132414</nct_id>
  </id_info>
  <brief_title>Cerebral NIRS Monitoring During Anesthesia in Neonates and Infants</brief_title>
  <official_title>Monitoring Of REgional Cerebral Oxygenation (rcSO2 ) With Near INFrared SpectrOscopy (NIRS) During Non-cardiac Surgery in Preterms, Neonates and Infants in Addition to Standard Monitoring to Guide Intraoperative Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The brain is a very vulnerable organ, especially in premature babies, newborns and infants.&#xD;
      However, during anesthesia, the oxygenation of the brain can only be monitored indirectly and&#xD;
      insufficiently. Near-infrared spectroscopy (NIRS) is an established monitoring method in&#xD;
      other areas (e.g., neonatology, cardiac anesthesia), which provides non-invasive information&#xD;
      about the regional oxygen supply of the brain. The integration of this monitoring device into&#xD;
      the anaesthesiological care for neonates and infants could reduce the risk of cerebral&#xD;
      hypoxia. The planned study investigates whether the use of NIRS in anesthetized children up&#xD;
      to 6 months can prevent or influence the occurrence of cerebral hypoxia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral hypoxic burden</measure>
    <time_frame>1 day</time_frame>
    <description>Time under 65% cerebral oxygen saturation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluid administration</measure>
    <time_frame>1 day</time_frame>
    <description>ml/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Vasopressor or Inotrope administered</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with erythrocyte administration</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of inspired oxygen</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cerebral Oxygenation</condition>
  <arm_group>
    <arm_group_label>NIRS open</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebral NIRS monitoring applied and visible to caregiver. Interventions according to protocol in phases of cerebral hypoxia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIRS blinded</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>NIRS monitoring applied and masked for caregiver.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NIRS open</intervention_name>
    <description>Treatment according to protocol in phases of cerebral hypoxia.</description>
    <arm_group_label>NIRS open</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Expected duration of Anesthesia &gt;45 minutes&#xD;
&#xD;
          -  Intervention/surgery in the operating room&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossibility to place cerebral NIRS sensor&#xD;
&#xD;
          -  Known cerebral pathology&#xD;
&#xD;
          -  Missing parental consent&#xD;
&#xD;
          -  Congenial cardiac condition with right to left shunt&#xD;
&#xD;
          -  Cardiac surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Heschl, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Heschl, M.D., Ph.D.</last_name>
    <phone>+4331638513027</phone>
    <email>stefan.heschl@medunigraz.at</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

